Mayo Clinic Ventures pumped in a share of the proceeds for Cadence Neuroscience, which is working on biomarker-powered neuromodulation therapies for drug resistant-focal epilepsy.

US-based neuromodulation therapy developer Cadence Neuroscience has collected $15m in a series A round involving Mayo Clinic Ventures, the corporate venturing vehicle for medical research company Mayo Clinic. The round was led by venture capital firm Jazz Venture Partners and also featured Mayo’s Benefactor Innovation Fund and nonprofit organisation Epilepsy Foundation of America. Cadence Neuroscience…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.